Protease action and generation of β-thromboglobulin-like protein followed by platelet activation

Resmi, K.R; Krishnan, Lissy K.

doi:10.1016/s0049-3848(02)00135-4

Cited by 11 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(10). A mixture of platelet growth factors (PGF) that include platelet‐derived growth factor, heparin‐binding platelet factor‐4, transforming growth factor β, and β‐thromboglobulin was prepared as per a published procedure (11).…”

Section: Methodsmentioning

confidence: 99%

“…For matrix preparation, a mixture of angiogenic growth factor (AGF) containing VEGF and FGF was prepared from bovine hypothalamus according to the method of Maciag et al (10). A mixture of platelet growth factors (PGF) that include platelet-derived growth factor, heparinbinding platelet factor-4, transforming growth factor b, and b-thromboglobulin was prepared as per a published procedure (11).…”

Section: Cell Isolation and Culturementioning

confidence: 99%

See 1 more Smart Citation

Design of Fibrin Matrix Composition to Enhance Endothelial Cell Growth and Extracellular Matrix Deposition for In Vitro Tissue Engineering

Pankajakshan

Krishnan

2009

Artificial Organs

View full text Add to dashboard Cite

Tissue-engineered blood vessel substitutes should closely resemble native vessels in terms of structure, composition, mechanical properties, and function. Successful cardiovascular tissue engineering requires optimization of in vitro culture environment that would produce functional constructs. The extracellular matrix (ECM) protein elastin plays an essential role in the cardiovascular system to render elasticity to blood vessel wall, whereas collagen is responsible for providing mechanical strength. The objective of this study was to understand the significance of various ECM components on endothelial cell (EC) growth and tissue generation. We demonstrate that, even though fibrin is a good matrix for EC growth, fibronectin is the crucial component of the fibrin matrix that enhances EC adhesion, spreading, and proliferation. Vascular EC growth factor is known to influence in vitro growth of EC, but, so far, ECM deposition in in vitro culture has not been reported. In this study, it is shown that incorporation of a mixture of hypothalamus-derived angiogenic growth factors with fibrin matrix enhances synthesis and deposition of insoluble elastin and collagen in the matrix, within 10 days of in vitro culture. The results suggest that a carefully engineered fibrin composite matrix may support EC growth, survival, and remodeling of ECM in vitro and impart optimum properties to the construct for resisting the shear stress at the time of implantation.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Cell Isolation and Culturementioning

confidence: 99%

Design of Fibrin Matrix Composition to Enhance Endothelial Cell Growth and Extracellular Matrix Deposition for In Vitro Tissue Engineering

Pankajakshan

Krishnan

2009

Artificial Organs

View full text Add to dashboard Cite

show abstract

“…To prepare a biomimetic niche (test) for ADMSCs differentiation, TCPS surface was deposited with fibrin matrix, according to the protocol of Prasad Chennazhy and Krishnan (2005) but with a fibroblast-specific composition of fibrinogen composite; 1 ml composite comprised human fibrinogen 2 mg, fibronectin (~0.2 mg), gelatin 0.2% (Sigma Chemicals, USA), hyaluronic acid 100 μg (in-house purified; Anilkumar et al, 2011) and human platelet growth factors (PGFs) 50 μg (in-house isolated; Resmi and Krishnan, 2002). Briefly, on a thrombinadsorbed surface, fibrinogen composite was layered to obtain a thin (< 1 μm) fibrin clot by the action of preadsorbed thrombin.…”

Section: Preparation Of Fibroblast-specific Niche (Fsn)mentioning

confidence: 99%

Matrix-directed differentiation of human adipose-derived mesenchymal stem cells to dermal-like fibroblasts that produce extracellular matrix

Unnikrishnan

Jayakumar

Krishnan

2014

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Commercially available skin substitutes lack essential non-immune cells for adequate tissue regeneration of non-healing wounds. A tissue-engineered, patient-specific, dermal substitute could be an attractive option for regenerating chronic wounds, for which adipose-derived mesenchymal stem cells (ADMSCs) could become an autologous source. However, ADMSCs are multipotent in nature and may differentiate into adipocytes, osteocytes and chondrocytes in vitro, and may develop into undesirable tissues upon transplantation. Therefore, ADMSCs committed to the fibroblast lineage could be a better option for in vitro or in vivo skin tissue engineering. The objective of this study was to standardize in vitro culture conditions for ADMSCs differentiation into dermal-like fibroblasts which can synthesize extracellular matrix (ECM) proteins. Biomimetic matrix composite, deposited on tissue culture polystyrene (TCPS), and differentiation medium (DM), supplemented with fibroblast-conditioned medium and growth factors, were used as a fibroblast-specific niche (FSN) for cell culture. For controls, ADMSCs were cultured on bare TCPS with either DM or basal medium (BM). Culture of ADMSCs on FSN upregulated the expression of differentiation markers such as fibroblast-specific protein-1 (FSP-1) and a panel of ECM molecules specific to the dermis, such as fibrillin-1, collagen I, collagen IV and elastin. Immunostaining showed the deposition of dermal-specific ECM, which was significantly higher in FSN compared to control. Fibroblasts derived from ADMSCs can synthesize elastin, which is an added advantage for successful skin tissue engineering as compared to fibroblasts from skin biopsy. To obtain rapid differentiation of ADMSCs to dermal-like fibroblasts for regenerative medicine, a matrix-directed differentiation strategy may be employed. Copyright © 2014 John Wiley & Sons, Ltd.

show abstract

“…CTAP-III is converted from a precursor PBP, the major megakaryocytes variant, during megakaryocyte maturation and platelet formation [29]. After its release from platelet α-granules, CTAP-III can be proteolytically cleaved to β-TG [26,30] and/or NAP-2 [31,32] with chemotactic activity [33]. The exact mechanism of the cleavage regulation is unknown.…”

Section: Introductionmentioning

confidence: 99%

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

et al. 2013

View full text Add to dashboard Cite

With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.

show abstract

Protease action and generation of β-thromboglobulin-like protein followed by platelet activation

Cited by 11 publications

References 21 publications

Design of Fibrin Matrix Composition to Enhance Endothelial Cell Growth and Extracellular Matrix Deposition for In Vitro Tissue Engineering

Design of Fibrin Matrix Composition to Enhance Endothelial Cell Growth and Extracellular Matrix Deposition for In Vitro Tissue Engineering

Matrix-directed differentiation of human adipose-derived mesenchymal stem cells to dermal-like fibroblasts that produce extracellular matrix

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

Contact Info

Product

Resources

About